Business
Tempest to Present at Two Upcoming Investor Conferences in November
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing
About this update from Tempest Therapeutics, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the following investor conferences in November: Jefferies London Healthcare Conference – Company presentation available on-demand Thursday, November 18, 2021 at 8:00 a.m. GMTPiper Sandler 33rd Annual Virtual Healthcare Conference – Fireside chat available on-demand Monday, November 22, 2021 at 10:00 a.m. ET To access the live or archived recording of the company presentaions, please visit the investor section of the Tempest website at https://ir.tempesttx.com. About Tempest Therapeutics Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARα, respectively. Both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. In collaboration with F. Hoffman La Roche, TPST-1120 is also advancing through a first line, global, randomized Phase 1b/2 clinical study evaluating TPST-1120 in combination with the standard-of-care regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. Tempest is headquartered in South San Francisco. More information about Tempest can be found on the company’s website at www.tempesttx.com. Investor Contact: Sylvia WheelerWheelhouse Life Science [email protected] Media Contact: Aljanae Reynolds Wheelhouse Life Science [email protected] \nSource: Tempest Therapeutics","length":4247,"tagName":"div"}]